Joseph Edelman

Perceptive Advisors acquires 700,000 OBIO shares (+15.2% increase) at $2.75 while stock down 63.8% from 52-week high, amid unprofitability and declining revenue.

Perceptive Advisors LLC, a 10% shareholder, purchased 700,000 shares at $2.75 on 2025-08-01, increasing holdings to 5.29M shares. The transaction occurs with Orchestra BioMed trading at $2.67 (current price), down 63.8% from its 52-week high of $7.38. The company faces material headwinds: latest quarterly revenue is $868,000, full-year net income was negative at $-18.8M, and annual revenue growth is negative at -4.4%. The insider's cross-ticker track record shows a mixed pattern—14 prior buys averaged +122.0% 30-day returns, but this outsized performance does not extend reliably to single-ticker performance and may reflect selection bias across multiple positions. The fundamental deterioration (negative profitability, revenue decline) combined with the substantial price markdown from peak valuations raises questions about whether this represents accumulation at distressed levels or conviction in a turnaround narrative that remains unvalidated by current operating metrics.

ACRV: 10% owner Perceptive Advisors sells 736,767 shares (19.2% of holdings) for $1.0M as stock down 78.1% in 90 days

Perceptive Advisors LLC, a 10% owner, executed two separate sales totaling 736,767 shares for $1,017,919.45 on 2025-04-30 and 2025-05-01 at a blended average price of $1.38. This sale reduced holdings by 19.2%, from 3,840,906 shares to 3,104,139 shares. The timing is significant: Acrivon's stock has declined 78.1% over the past 90 days and is trading at $1.33, down 86.7% from its 52-week high of $10.00. The company reported a net loss of $22,441,000 and has a market cap of only $41,697,468.40, suggesting structural profitability challenges. Against the insider's historical cross-ticker track record showing a 57.14% 90-day win rate on prior buys, his same-ticker history at ACRV is unfavorable—a prior April 2024 buy at this company produced a -15.8% 90-day return. The current liquidation pattern, occurring after three prior consecutive sells at this ticker within days, reflects active diversification of a 10% concentrated stake as the company's valuation has cratered.

10% owner PERCEPTIVE ADVISORS LLC sold 1,519,952 shares at blended average $1.81 across 3 separate sales in April; post-transaction holding 3,840,906 shares (-28.4% reduction)

PERCEPTIVE ADVISORS LLC, a 10% shareholder, executed 3 separate open-market sales in late April totaling 1,519,952 shares for $2,744,946.03 at a blended average price of $1.81, reducing holdings by 28.4% from 5,360,858 to 3,840,906 shares. The company is unprofitable with net income of $-22,441,000.00 and market cap of $45,146,131.20, while the stock has collapsed 85.6% from its 52-week high of $10.00 to current price of $1.44. The insider's cross-ticker track record shows strong buy-side accuracy (19 prior buys with 90-day win rate 64.71%), but at this specific ticker, the prior buy from 2024-04-11 declined 15.8% over 90 days, suggesting limited predictive edge in ACRV. A material reduction in stake by a significant shareholder during severe equity decline warrants investor scrutiny of underlying business fundamentals.

10% owner PERCEPTIVE ADVISORS LLC sold 3.40M shares of ALDX at $1.42 on 2025-04-03, reducing stake to 5.88M shares; stock now -72.1% from 52-week high.

PERCEPTIVE ADVISORS LLC, a 10% shareholder, divested 3,400,000 shares (36.7% reduction in holdings) at $1.42 per share for $4,828,000.00. The current price of $1.95 is -72.1% from the 52-week high of $6.98, and the stock has declined 69.3% over the past 30 days and 61.8% over 90 days. Across his prior ALDX trades, the insider's timing record at this ticker has been poor: 4 of 5 prior buys resulted in negative 90-day returns, with only 1 of 5 prior buys posting a positive 90-day outcome. The company remains unprofitable with net income of $-15,112,983.00 and a market cap of $116,431,875.30. While the insider's cross-ticker track record shows strong performance (66.67% 90-day win rate, +236.3% average 90d return on 20 buys), his specific execution at ALDX has not replicated that success, and this large stake reduction occurs against significant recent price deterioration and negative fundamentals.

Director Joseph Edelman buys 5,000,000 shares of SLDB at $4.03; holdings increase to 11,833,539 shares

Joseph Edelman, a Director at Solid Biosciences, purchased 5,000,000 shares (5.00M shares) at $4.03 on 2025-02-19 for a total value of $20,150,000.00 ($20.2M). This transaction increased his holdings by 73.2%, bringing his post-transaction position to 11,833,539 shares (11.83M shares) from 6,833,539 shares (6.83M shares). The substantial size of this acquisition—$20.2M in capital deployment—and the proportional expansion of his ownership stake represent a meaningful increase in personal capital committed to the company and suggest sustained engagement with the firm's direction and prospects.

Director Joseph Edelman buys 1,250,000 shares of MGTX at $4.00; holdings rise to 12,531,103 shares

Joseph Edelman, a Director, purchased 1,250,000 shares at $4.00 on 2024-08-12 for a total value of $5,000,000.00. This transaction increased his holdings from 11,281,103 shares to 12,531,103 shares, representing a net change of purchased 1,250,000 shares or +11.1% versus pre-transaction holdings. The purchase represents a seven-figure capital commitment from a board member at a material share count relative to his existing position.